

CORRECTION

Open Access



Correction: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL™)

Christopher Kemper¹, Dariush Behnam², Shaun Brothers^{3,4}, Claes Wahlestedt^{3,4}, Claude-Henry Volmar^{3,4}, Daniel Bennett⁵ and Marshall Hayward^{3*}

Correction: *AAPS Open* 8, 11 (2022)
<https://doi.org/10.1186/s41120-022-00058-1>

Following publication of the original article (Kemper et al., 2022), the authors identified an error in the author name Dariush Behnam. The family name was incorrectly used throughout the article.

The incorrect author name is: Dariush Benham

The correct author name is: Dariush Behnam

The sentence currently in the Introduction section currently reads:

JOTROL™ is a micellar 10% resveratrol solubilization formulation that is thought to increase the amount of resveratrol and metabolite concentrations in the blood via the lymphatic system (Benham and Hayward 2022).

The sentence should read:

JOTROL™ is a micellar 10% resveratrol solubilization formulation that is thought to increase the amount of resveratrol and metabolite concentrations in the blood via the lymphatic system (Behnam and Hayward 2022).

The Authors' contributions section currently reads:

DBenham, SB, CW, CHV, and MH were engaged in early preclinical and clinical development and reporting of observations with JOTROL™ and were engaged in the

authorship of this manuscript. CK and MH were engaged with specific design and interpretation elements of the PK study and authorship of the manuscript. DBennett was engaged with bioanalytical aspects of the PK study and authorship of the clinical study report and contributed to the editing of this manuscript. The author(s) read and approved the final manuscript.

The Authors' contributions section should read:

DBenham, SB, CW, CHV, and MH were engaged in early preclinical and clinical development and reporting of observations with JOTROL™ and were engaged in the authorship of this manuscript. CK and MH were engaged with specific design and interpretation elements of the PK study and authorship of the manuscript. DBennett was engaged with bioanalytical aspects of the PK study and authorship of the clinical study report and contributed to the editing of this manuscript. The author(s) read and approved the final manuscript.

The Competing Interest section currently reads:

CK is a paid consultant of Jupiter Neurosciences (Jupiter).

DBenham is a principle of the company which has licensed technology to Jupiter but has no direct remunerative relationship with Jupiter. Aquanova owns no equity but does have unexecuted stock options.

SB and CW are Jupiter founders and have an equity position in the company.

They are also paid consultants of Jupiter. Both hold unexecuted stock options.

CV is a paid consultant of Jupiter and has unexecuted stock options.

The original article can be found online at <https://doi.org/10.1186/s41120-022-00058-1>.

*Correspondence: m.hayward@jupiterneurosciences.com

³ Jupiter Neurosciences Inc., 1001 US Highway North Suite 504, Jupiter, FL 33458, USA

Full list of author information is available at the end of the article

DBennett has no direct financial relationship with Jupiter other than as a paid employee of Syneos Health, the CRO for the PK study.

MH is a founder, employee, and member of the board of directors of Jupiter, has an equity position in Jupiter, is remunerated per an employment contract, and holds unexecuted stock options.

The Competing Interest section should read:

CK is a paid consultant of Jupiter Neurosciences (Jupiter).

DBehnam is a principle of the company which has licensed technology to Jupiter but has no direct remunerative relationship with Jupiter. Aquanova owns no equity but does have unexecuted stock options.

SB and CW are Jupiter founders and have an equity position in the company.

They are also paid consultants of Jupiter. Both hold unexecuted stock options.

CV is a paid consultant of Jupiter and has unexecuted stock options.

DBennett has no direct financial relationship with Jupiter other than as a paid employee of Syneos Health, the CRO for the PK study.

MH is a founder, employee, and member of the board of directors of Jupiter, has an equity position in Jupiter, is remunerated per an employment contract, and holds unexecuted stock options.

The reference current reads:

Behnam D, Hayward M (2022) US patent 10,780,056

The reference should read:

Behnam D, Hayward M (2022) US patent 10,780,056

The author group, affected citation, reference and Declarations have been updated above and the original article (Kemper et al., 2022) has been corrected.

Author details

¹Pharma Navigators LLC, 25 Dix Lane, Lawrenceville, NJ 08648, USA.

²Aquanova AG, Darmstadt, Germany. ³Jupiter Neurosciences Inc., 1001 US

Highway North Suite 504, Jupiter, FL 33458, USA. ⁴Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL 33136,

USA. ⁵Syneos Health, 301 College Road East, Princeton, NJ, USA.

Published online: 27 July 2022

Reference

Kemper C, Behnam D, Brothers S et al (2022) Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL™). *AAPS Open* 8:11. <https://doi.org/10.1186/s41120-022-00058-1>

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)